New drug combo for stomach cancer with spread to abdomen
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called BioTTT001 combined with chemotherapy (SOX) and another drug (toripalimab) for stomach cancer that has spread to the lining of the abdomen. It is for people who have not had treatment for advanced disease or whose cancer came back more than 6 months after earlier treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Stomach cancer that has spread to the lining of the abdomen (peritoneal metastasis)
- Cancer is HER2-negative (a type of protein test)
- Have not received any systemic treatment for advanced disease, or if you had chemo before surgery, your cancer came back more than 6 months later
- Good blood counts, kidney and liver function, and heart function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BioTTT001 combined with toripalimab and regorafenib for people with colorectal cancer that has spread to the liver. It is for those who have tried at least two prior treatments or cannot have standard therapies.
This trial tests a new combination of treatments for stomach cancer that has spread to the lining of the abdomen. It uses an immunotherapy drug (tislelizumab) with chemotherapy (SOX) and heated chemotherapy directly into the abdomen (HIPEC) to see if it works better than standard care.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
This trial tests a combination of two immunotherapy drugs (iparomlimab/tuvonralimab) plus chemotherapy (XELOX) in people with advanced stomach or gastroesophageal junction cancer that is HER2-negative and has low PD-L1 levels. It aims to see if this treatment can help shrink tumors or slow the disease.
This trial tests a new treatment plan for advanced stomach cancer using chemotherapy, anti-angiogenesis therapy (to cut off tumor blood supply), and immunotherapy (to help your immune system fight cancer). The goal is to see if this combination works better before surgery.
Hear when a new Gastric Cancer, Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.